Примери за използване на Efficacy outcomes на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Efficacy Outcome.
Secondary efficacy outcome measures were disease control rate(DCR;
Secondary efficacy outcome measures were ORR
Secondary efficacy outcome measures were OS
Time to first occurrence of primary efficacy outcome(stroke, myocardial infarction,
The prespecified net clinical benefit(primary efficacy outcome plus major bleeding events)
The prespecified net clinical benefit(primary efficacy outcome plus major bleeding events)
PFS assessed by blinded independent radiology review(BIR) was a key secondary efficacy outcome.
Key secondary efficacy outcome measures were investigator-assessed objective response rate(ORR)
Fibrosis Scores of 4(cirrhosis) were comparable to overall responses on all efficacy outcome measures(all patients had compensated liver disease).
The numbers of subjects experiencing an efficacy outcome event were 25(6.9%)
The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction(MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure(coronary, carotid, or peripheral).
The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction(MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events,
Efficacy outcomes by subgroups are described in the table below.
Table 10: ECU-MG-301 Efficacy Outcomes Change from Baseline to Week 26.
Key Efficacy Outcomes in Study 1 in Episodic Migraine Efficacy Endpoint.
Key Efficacy Outcomes for Partial Onset Seizure Frequency per 28 Days Study.
Key Efficacy Outcomes in Study 2 in Chronic Migraine Efficacy Endpoint.
Table 7 Key efficacy outcomes from PURSUIT- Induction
Table 10 Key efficacy outcomes in PsA001 clinical trial(percent of patients) Response.